According to Dimension Market Research, the GCC Radiopharmaceuticals Market is estimated at USD 218.4 million in 2026 and projected to reach USD 682.6 million by 2035, at a CAGR of 13.5% from 2026 to 2035. Diagnostic products account for most estimated revenue in 2026, while therapeutic radiopharmaceuticals are forecast to grow faster as regional oncology centers expand their services.
The outlook depends on supply as well as hospital demand. Some products contain radioisotopes with short half-lives, which limits the time available between production and clinical use. As Saudi Arabia and the UAE develop their nuclear medicine services, access to reliable regional supply becomes increasingly important to hospital procurement and service planning.
What Is the GCC Radiopharmaceuticals Market?
The market covers radioactive pharmaceutical products used in nuclear medicine for diagnosis and treatment across the Gulf Cooperation Council. Diagnostic products support imaging methods such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). Therapeutic products deliver targeted radiation for selected clinical uses. The report examines the market by radioisotope, product type, production source, application, and end user, including oncology, cardiology, neurology, and endocrinology.
Get a Free Sample of the GCC Radiopharmaceuticals Market Report
If you are evaluating nuclear medicine demand, comparing diagnostic and therapeutic portfolios, or assessing regional supply opportunities, request a sample to review the report’s scope and segmentation.
Request a Free Sample
https://dimensionmarketresearch.com/request-sample/gcc-radiopharmaceuticals-market/
Diagnostics Lead Revenue as Therapeutics Grow Faster
Diagnostic radiopharmaceuticals are expected to account for 68.9% of GCC market revenue in 2026, supported by established and expanding PET and SPECT imaging infrastructure. Fluorine-18 derivatives lead the radioisotope breakdown with an estimated 42.6% share. DMR links that position to the use of fluorine-18 imaging agents in oncology PET services across hospitals and cancer centers.
Therapeutic radiopharmaceuticals are projected to grow at an 18.4% CAGR from 2026 to 2035, the highest rate in the product-type breakdown. The report highlights theranostics, an approach that pairs diagnostic and therapeutic products directed at the same biological target. For suppliers, this creates an opportunity to support oncology centers that are building both imaging and treatment services and need to coordinate access to the associated products.
Hospitals and Oncology Anchor Regional Demand
Oncology is the leading application, with an estimated 51.8% share in 2026. Hospitals lead by end user at 57.4%. Saudi Arabia and the UAE are investing in nuclear medicine and oncology centers that can serve domestic patients and attract patients from neighboring markets. For suppliers assessing regional demand, those investments help identify where procurement may be concentrated and where partnerships with hospitals or cancer centers may matter most.
Supply Reliability Shapes Investment and Competition
Cyclotrons lead by production source with an estimated 54.3% share in 2026. The region continues to rely on imports for certain radioisotopes. Short delivery windows make supply disruptions particularly consequential, while adding regional production capacity requires capital and specialized staff. DMR identifies investment in regional cyclotrons and radiopharmacies as an opportunity to reduce import dependence for selected products and improve continuity of supply.
The report profiles suppliers including GE HealthCare and Jubilant Radiopharma and describes a competitive landscape that also includes government-backed facilities and hospital groups with nuclear medicine capabilities. Portfolio breadth and established hospital relationships matter alongside supply reliability and distribution expertise. For buyers, those factors affect whether a supplier can meet the needs of a single center or support a network as its imaging and treatment services expand.
Explore the Complete GCC Radiopharmaceuticals Market Analysis
Use the full report to compare demand by radioisotope and application, assess the outlook for diagnostics and therapeutics, and review opportunities in regional production and distribution. The verified checkout page offers license selection.
Proceed to Checkout
https://dimensionmarketresearch.com/checkout/gcc-radiopharmaceuticals-market/
Frequently Asked Questions
1. How large is the GCC Radiopharmaceuticals Market?
DMR estimates the market at USD 218.4 million in 2026 and projects USD 682.6 million by 2035.
2. What is the projected market CAGR?
The market is projected to grow at a CAGR of 13.5% from 2026 to 2035.
3. Which product type leads the market?
Diagnostic radiopharmaceuticals lead by type, with an estimated 68.9% share in 2026.
4. Which application accounts for the most revenue?
Oncology leads by application, with an estimated 51.8% share in 2026.
5. What limits regional supply?
The GCC relies on imports for some radioisotopes, and products with short half-lives require rapid delivery. Local capacity expansion also requires substantial investment and specialized expertise.
Conclusion
Diagnostic imaging anchors GCC radiopharmaceutical demand, while therapeutic services offer a faster-growing opportunity through 2035. Regional investment in production and radiopharmacy capacity can help suppliers and healthcare providers serve more centers while reducing reliance on imported supply for selected products.
Related Radiopharmaceutical Market Insights
The Radiopharmaceuticals Market Size report projects global revenue of USD 9,876.2 million by 2033 and identifies diagnostic products as the leading type in its 2024 estimates.
The U.S. Radiopharmaceuticals Market Share report estimates that diagnostic radiopharmaceuticals accounted for 74.0% of U.S. revenue by type in 2025.
The Japan Radiopharmaceuticals Market Growth report projects revenue to rise from USD 1.6 billion in 2026 to USD 3.9 billion by 2035.
